PDCD1 and neoplasm: PARP inhibitor‐induced DNA damage can lead to an adaptive upregulation of PD‐L1 on tumor cells, which, while potentially a resistance mechanism, can be effectively counteracted by concurrent PD‐1/PD‐L1 blockade, thereby restoring T‐cell function and boosting antitumor immunity [132].